The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,022.00
Bid: 2,020.00
Ask: 2,022.00
Change: 20.00 (1.00%)
Spread: 2.00 (0.099%)
Open: 2,014.00
High: 2,028.00
Low: 2,010.00
Prev. Close: 2,002.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

3 Apr 2023 09:27

RNS Number : 1243V
Hikma Pharmaceuticals Plc
03 April 2023
 

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 3 April 2023

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 

Period of return

From: 1 October 2022

To:

31 March 2023

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 Ordinary Shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 Ordinary Shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 Ordinary Shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 Ordinary Shares of 10 pence

The Hikma Pharmaceuticals plc 2004 Stock Option Plan has expired. No further shares may be issued under the block listing and no further block listing returns will be made in respect of this expired Plan; therefore, the block listing is hereby cancelled. In accordance with LR3.5.6R, a final block listing return in respect of this block listing is set out above in the prescribed form.

 

Name of contact:

Hussein Arkhagha

Telephone number of contact:

+44(0)20 7399 2760

 

 

Block Listing Six Monthly Return

 

Date: 3 April 2023

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 October 2022

To:

31 March 2023

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 57,502 Ordinary Shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 Ordinary Shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 0 Ordinary Shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 Ordinary Shares of 10 pence

The Hikma Pharmaceuticals plc 2005 Long-Term Incentive Plan has expired. No further shares may be issued under the block listing and no further block listing returns will be made in respect of this expired Plan; therefore, the block listing is hereby cancelled. In accordance with LR3.5.6R, a final block listing return in respect of this block listing is set out above in the prescribed form.

 

Name of contact:

Hussein Arkhagha

Telephone number of contact:

+44(0)20 7399 2760

 

Block Listing Six Monthly Return

 

Date: 3 April 2023

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009 MIP")

Period of return

From: 1 October 2022

To:

31 March 2023

Balance of unallotted securities under scheme(s) from previous return:

2009 MIP: 0 Ordinary Shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2009 MIP: 0 Ordinary Shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2009 MIP: 0 Ordinary Shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

2009 MIP: 0 Ordinary Shares of 10 pence

The Hikma Pharmaceuticals plc 2009 Management Incentive Plan has expired. No further shares may be issued under the block listing and no further block listing returns will be made in respect of this expired Plan; therefore, the block listing is hereby cancelled. In accordance with LR3.5.6R, a final block listing return in respect of this block listing is set out above in the prescribed form.

 

Name of contact:

Hussein Arkhagha

Telephone number of contact:

+44(0)20 7399 2760

 

 

Block Listing Six Monthly Return

 

Date: 3 April 2023

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP") and Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP") (together "the Plans")

Period of return

From: 1 October 2022

To:

31 March 2023

Balance of unallotted securities under scheme(s) from previous return:

2018 MIP: 414,112 Ordinary Shares of 10 pence

EIP: 354,962 Ordinary Shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

The Plans: 1,200,000 Ordinary Shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2018 MIP: 294,737 Ordinary Shares of 10 pence

EIP: 176,424 Ordinary Shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

The Plans: 1,497,913 Ordinary Shares of 10 pence

 

Name of contact:

Hussein Arkhagha

Telephone number of contact:

+44(0)20 7399 2760

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPUAPCUPWURW
Date   Source Headline
22nd Jun 202011:20 amRNSDirector/PDMR Shareholding
2nd Jun 20209:31 amRNSTotal Voting Rights
22nd May 20207:00 amRNSHikma receives FDA approval for generic Vascepa®
20th May 20203:42 pmRNSDirector/PDMR Shareholding
13th May 20201:28 pmRNSDirector/PDMR Shareholding
1st May 202011:30 amRNSTotal Voting Rights
30th Apr 202012:00 pmRNSResult of AGM
30th Apr 20207:00 amRNSDirectorate Change
30th Apr 20207:00 amRNSTrading Statement
16th Apr 20203:07 pmRNSDirector/PDMR Shareholding
14th Apr 20202:30 pmRNSBlock listing Interim Review
2nd Apr 20207:00 amRNSAGM Update
31st Mar 20207:00 amRNSHikma's favourable ruling in generic Vascepa®
24th Mar 202010:52 amRNSDirector/PDMR Shareholding
19th Mar 202012:00 pmRNSAnnual Financial Report
28th Feb 202012:27 pmRNSDirector/PDMR Shareholding
28th Feb 202012:26 pmRNSDirector/PDMR Shareholding
28th Feb 202012:23 pmRNSDirector/PDMR Shareholding
27th Feb 20204:40 pmRNSDirector/PDMR Shareholding
27th Feb 20204:35 pmRNSBoard Committee Changes
27th Feb 20207:05 amRNSHikma enters agreement to commercialise Ryaltris™
27th Feb 20207:00 amRNSFinal Results
4th Feb 20202:06 pmRNSTotal Voting Rights
4th Feb 20209:07 amRNSNotice of Results
15th Jan 20209:46 amRNSDirector/PDMR Shareholding
15th Jan 20209:44 amRNSDirector/PDMR Shareholding
9th Jan 20208:00 amRNSHikma announces agreement with Arecor
2nd Jan 202010:56 amRNSTotal Voting Rights
10th Dec 201912:06 pmRNSCivica Rx and Hikma announce shipment of medicines
2nd Dec 20195:12 pmRNSTotal Voting Rights
27th Nov 20197:00 amRNSHikma completes FDA response for generic Advair®
21st Nov 20192:47 pmRNSDirector/PDMR Shareholding
8th Nov 201911:17 amRNSBlock Listing Application
7th Nov 20197:00 amRNSTrading Statement
5th Nov 20199:34 amRNSTotal Voting Rights
4th Oct 20191:36 pmRNSHolding(s) in Company
1st Oct 20193:15 pmRNSBlock listing Interim Review
1st Oct 20193:02 pmRNSTotal Voting Rights
17th Sep 20199:00 amRNSHikma launches prefilled syringes in the US
10th Sep 201910:05 amRNSNotice of Accession of Guarantor
6th Sep 20193:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20195:13 pmRNSTotal Voting Rights
13th Aug 201910:20 amRNSDirector/PDMR Shareholding
9th Aug 20199:00 amRNSHikma expands nasal spray capabilities
9th Aug 20197:00 amRNSHalf-year Report
1st Aug 20193:04 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSHikma and Richter sign agreement for cariprazine
23rd Jul 20199:00 amRNSHikma and Civica Rx sign long-term agreement
8th Jul 20199:00 amRNSNotice of Results
2nd Jul 20195:54 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.